Mitomicină Accord (Mitomycin)

Mitomycin is reduced inside tumour cells to a highly reactive alkylating species. This species forms covalent cross‑links between DNA strands, blocking replication and transcription. The DNA damage triggers cellular repair mechanisms that ultimately lead to apoptosis of rapidly dividing cancer cells.

The exact dose is determined by the prescribing oncologist based on the specific cancer type, disease stage, patient body‑surface area, renal and hepatic function, and any concurrent therapies. Dosing regimens are individualized and should follow established clinical protocols.

Mitomycin is classified as pregnancy category unknown and is generally avoided in pregnant or nursing patients because of potential fetal toxicity and excretion in breast milk. Women of child‑bearing potential should use effective contraception during treatment and for a period recommended by their physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and the necessary import documentation.

Mitomycin shares the DNA‑cross‑linking mechanism common to alkylating agents but is distinguished by its requirement for enzymatic activation within tumour cells, giving it activity in hypoxic environments. Compared with agents such as cyclophosphamide, mitomycin often shows greater potency in bladder cancer but may have a higher risk of specific toxicities like hemolytic‑uremic syndrome.

Mitomicină Accord should be stored in a refrigerator at 2 °C to 8 °C. The product must be kept in its original packaging, protected from light, and must not be frozen or shaken. If a temporary temperature excursion occurs, consult the supplier before use.

The medication is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting, following aseptic technique. Dosage and infusion rate are determined by the treating physician based on the therapeutic protocol.

Serious risks include bone‑marrow failure leading to severe pancytopenia, hemolytic‑uremic syndrome with renal impairment, pulmonary toxicity such as interstitial pneumonitis, and secondary malignancies. Patients should be monitored closely for signs of infection, bleeding, renal dysfunction, and respiratory symptoms throughout treatment.

Mitomicină Accord is contraindicated in patients with known hypersensitivity to mitomycin or any component of the formulation. It should also be avoided in individuals with severe renal impairment, uncontrolled infections, or those receiving concurrent high‑dose radiation to the same treatment field unless the benefit outweighs the risk.